Octagon Capital Advisors LP Unicycive Therapeutics, Inc. Call Options Transaction History
Octagon Capital Advisors LP
- $449 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding UNCY
# of Institutions
32Shares Held
50.8MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT11MShares$6.48 Million5.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT10.4MShares$6.13 Million0.41% of portfolio
-
Vivo Capital, LLC Palo Alto, CA9.97MShares$5.88 Million1.54% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3 Million0.53% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$2.95 Million0.01% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.88M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...